Maxim lowered the firm’s price target on Silexion Therapeutics (SLXN) to $5 from $9 and keeps a Buy rating on the shares after its Q4 results. The company is progressing with its SIL-204, an updated formulation of its prior LODER therapy, a KRAS targeting siRNA therapy for treating non-resectable, locally advanced pancreatic cancer, though the firm is reducing its price target due to the additional dilution from the recent capital raise and warrant exercises, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLXN:
- Biotech Alert: Searches spiking for these stocks today
- Silexion Therapeutics Receives Buy Rating from Naz Rahman Following Promising SIL-204 Pre-Clinical Results
- 3 Penny Stocks to Watch Now, 3/6/25
- Silexion Therapeutics Reports Positive Data for SIL204
- Silexion reports initial data from systemic administration of SIL204
Questions or Comments about the article? Write to editor@tipranks.com